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To the Editor: Vanbelleghem et al.1 (21 March 2007) imply
that the Normal Hematocrit study2 (NHS) should not be
used as a rationale for proposing conservative hemoglobin
targets (a minimum hemoglobin of 10 g/dl used in the UK
guidelines). Implicit in their discussion is that the NHS is not
generalizable to the dialysis population, echoing a similar
refrain made by Macdougall and Ritz3 several years ago. On
the contrary, I would submit that the NHS is quite
representative of the dialysis population. Most importantly,
as has been noted elsewhere,4 the 24% mortality observed in
NHS was very similar to the 20.4% mortality per 1000
patients reported by the United States Renal Data System.
Indeed, cardiovascular disease is highly prevalent among the
dialysis population,5 as it was in the NHS. It is also important
to note that while the NHS was stopped by the Data and
Safety Monitoring Board, discontinuation was because of
safety concerns with regards to mortality.2 The authors of the
NHS state ‘(The) Study was halted when differences in
mortality between the groups were recognized as sufficient to
make it very unlikely that continuation of the study would
reveal a benefit for the normal-hematocrit group and the
results were nearing the statistical boundary of a higher
mortality rate in the normal hematocrit group.’ Indeed, the
NHS represents the largest randomized controlled study
conducted in dialysis patients examining hemoglobin targets.
Quite curiously, despite the mortality signal from NHS, this
question has not subsequently been examined in any
similarly sized study in dialysis patients. In the wake of
recent data in the non-dialysis chronic kidney disease
patients6,7 that reinforce the safety signal that emerged from
the NHS, the FDA black box advisory,8 and the less than
compelling quality of life benefits4 for a higher hemoglobin
target, surely a prudent strategy is to aim for the lowest
possible hemoglobin level needed to avoid blood transfusions
and optimize quality of life.
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We thank Dr Singh1 for his comments on our recent
publication comparing current major guidelines on the
Kidney Disease: Improving Global Outcomes (KDIGO)
website.2 His expressed concern about the generalizability
of the Normal Hematocrit Study (NHS)3 is quite appro-
priate. The guidelines are currently under re-examination
by guideline development groups in light of recent data
from the CREATE and CHOIR studies on the correction of
anemia in chronic kidney disease with erythropoiesis-
stimulating agents.4,5 This is well beyond the actual
message of our article, which was that nephrology guide-
lines worldwide come to different recommendations and
evidence grading, in spite of being based on the same
literature.2 As such, the paper mentioned the UK anemia
guideline to be discordant from other major guidelines,
but never suggested that the UK guidelines or any other
guidelines were wrong or should be discarded because of
this discordance. Importantly, as the averages in the low-
hemoglobin groups in the CREATE and CHOIR studies
were higher than 11 g/dl, there are still no data to comment
unequivocally on any target hemoglobin below 11 g/dl, as
do the UK guidelines.
The CREATE and CHOIR studies were not referenced in
our article because neither had appeared in print when the
paper was submitted for publication. Additionally, their
results had not been included in the evidence tables of any
published guidelines. This analysis is currently under way
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and will be included on the KDIGO website when
published.
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Advisory about gadolinium calls
for caution in the treatment of
uremic patients with lanthanum
carbonate
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To the Editor: The FDA issued advisories concerning the risk
for patients with renal failure who receive gadolinium-chelates
for developing a sometimes fatal disorder called Nephrogenic-
Fibrosis-Dermopathy (NFD)/Nephrogenic-Systemic-Fibrosis
(NSF).1 Although the disease mechanism has yet to be
elucidated, there is consensus that NFD/NFS could be associated
to the release of free gadolinium in the tissues. The cells may act
as sponges for the free-gadolinium ions by exploiting (and thus
interfering) the calcium regulatory machinery.2
Gadolinium is the 64th element of the periodic table at the
center of the lanthanide series (14 elements) (Figure 1). It is
known that all the members of the series display very close
physical-chemical characteristics yielding trivalent ions
whose (very small) differences in their chemical behavior
are essentially determined by the changes in the mass to
charge ratio.3
The use of lanthanum-carbonate salts as chelating agents
might have some analogies with what we are learning from
the gadodiamide story. Lanthanum-carbonate has been
selected for its insolubility. However, it has been reported
that lanthanum concentration is increased 10-fold in blood
and fivefold in bone after short-term supplementation.4,5
What’s about long-term treatments? Equilibrium shifts and
transmetallation reactions may lead to unexpected interfer-
ences with basic physiological processes and the upsurge of
diseased states as shown with gadodiamide. Clearly, more
work appears necessary to assess potential toxic effects
associated to the use of lanthanide-based drugs.
By now, as many uremic patients are taking lanthanum-
carbonate as phosphate-binder, nephrologists are strongly
recommended to look at any symptoms evoking NSF/NSD in
post-marketing drug-safety surveillance system.
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Figure 1 | Periodic table of the elements: gadolinium (Gd) belongs to the lanthanide series.
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